You have 9 free searches left this month | to do more

ublituximab

Ublituximab is a drug used to treat Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, and other conditions. Ublituximab is being actively studied in 14 studies and prior, has been studied in 9.

Top SponsorsTop SitesTop Investigators
TG Therapeutics, Inc.TG Therapeutics Investigational Trial SiteAmitkumar Mehta, MD
City of Hope Medical CenterCity of Hope Medical CenterJennifer R. Brown, MD, PhD
Jennifer R. Brown, MD, PhDTG Therapeutics RMS Investigational Trial SiteYazeed Sawalha
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Suspended
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Aurora, Colorado
    University of Colorado Hospital
2022-02-22
Feb 22, 2022
C
Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
W
Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • New York, New York
    Weill Cornell Medicine
2022-03-29
Mar 29, 2022
T
Active, not recruiting
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Fort Myers, Florida
  • +2 more
2022-03-22
Mar 22, 2022
C
Recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
2021-08-10
Aug 10, 2021
T
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
2022-03-22
Mar 22, 2022
U
Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
2021-09-08
Sep 8, 2021
T
Completed
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • New York, New York
  • +3 more
2021-12-21
Dec 21, 2021
J
Recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
  • +2 more
2021-05-10
May 10, 2021
Y
Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022
T
Completed
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Phoenix, Arizona
  • +12 more
2021-11-11
Nov 11, 2021
T
Completed
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Carlsbad, California
  • +13 more
2021-11-05
Nov 5, 2021
T
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +49 more
2022-03-22
Mar 22, 2022
T
Completed
  • Multiple Sclerosis
  • Ublituximab
  • Placebo
  • Phoenix, Arizona
  • +11 more
2021-06-22
Jun 22, 2021
T
Recruiting
  • B-Cell Lymphoma
  • Heidelberg, Victoria, Australia
  • +2 more
2022-03-22
Mar 22, 2022
T
Recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
2022-03-22
Mar 22, 2022
T
Completed
  • Non-Hodgkins Lymphoma
  • +6 more
  • Ublituximab
  • Huntsville, Alabama
  • +7 more
2019-10-01
Oct 1, 2019
J
Completed
  • Neuromyelitis Optica
  • Neuromyelitis Optica Spectrum Disorder
  • Ublituximab
  • Baltimore, Maryland
    Johns Hopkins University School of Medicine
2019-06-05
Jun 5, 2019
T
Completed
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Huntsville, Alabama
  • +17 more
2019-10-01
Oct 1, 2019
T
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Huntsville, Alabama
  • +86 more
2022-03-22
Mar 22, 2022
T
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Obinutuzumab
  • +3 more
  • Huntsville, Alabama
  • +153 more
2022-03-22
Mar 22, 2022
T
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +4 more
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +167 more
2022-03-22
Mar 22, 2022
T
Completed
  • Non-Hodgkins Lymphoma
  • +6 more
  • Huntsville, Alabama
  • +1 more
2014-10-09
Oct 9, 2014